Cannabinoids reduce melanoma cell viability and do not interfere with commonly used targeted therapy in metastatic melanoma in vivo and in vitro
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Biology, 12, 5, S. 706-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2023
- Ereignis
-
Veröffentlichung
- (wo)
-
Basel
- (wer)
-
MDPI AG
- (wann)
-
2023
- Urheber
-
Richtig, Georg
Kienzl, Melanie
Rittchen, Sonja
Roula, David
Eberle, Jürgen
Sarif, Zina
Pichler, Martin
Hoefler, Gerald
Heinemann, Akos
- DOI
-
10.3390/biology12050706
- URN
-
urn:nbn:de:bvb:384-opus4-1057913
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Richtig, Georg
- Kienzl, Melanie
- Rittchen, Sonja
- Roula, David
- Eberle, Jürgen
- Sarif, Zina
- Pichler, Martin
- Hoefler, Gerald
- Heinemann, Akos
- Universität Augsburg
- MDPI AG
Entstanden
- 2023
Ähnliche Objekte (12)
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Function and clinical implications of long non-coding RNAs in melanoma
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Clinical determinants of long-term survival in metastatic uveal melanoma
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Best of ASCO 2022: bladder cancer
Circulating tumor DNA as a marker for treatment response in metastatic melanoma patients using next-generation sequencing: a prospective feasibility study
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Function and clinical implications of long non-coding RNAs in melanoma
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Clinical determinants of long-term survival in metastatic uveal melanoma
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Best of ASCO 2022: bladder cancer
Circulating tumor DNA as a marker for treatment response in metastatic melanoma patients using next-generation sequencing: a prospective feasibility study
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Function and clinical implications of long non-coding RNAs in melanoma
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Clinical determinants of long-term survival in metastatic uveal melanoma
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Best of ASCO 2022: bladder cancer
Circulating tumor DNA as a marker for treatment response in metastatic melanoma patients using next-generation sequencing: a prospective feasibility study
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma